FAKTOR OPTIONSSCHEIN - GENMAB | Real-time Boerse Frankfurt Warrants 03:50:52 27/06/2024 pm IST | ||
| 0.043 EUR | -2.27% |
|
| Current month | -35.29% | ||
| 1 month | -32.31% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 27/24/27 | 0.043 | -2.27% |
| 26/24/26 | 0.044 | -2.22% |
| 25/24/25 | 0.045 | -2.17% |
| 24/24/24 | 0.046 | 0.00% |
| 21/24/21 | 0.046 | +6.98% |
Real-time Boerse Frankfurt Warrants
Last update June 27, 2024 at 03:50 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
BNP Paribas
|
| WKN | PH5GEN |
| ISIN | DE000PH5GEN4 |
| Date issued | 16/04/2020 |
| Strike | 1,791 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 18.77 € |
|---|---|
| Lowest since issue | 0.04 € |
| Spread | 0.001 € |
| Spread % | 2.27% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,791
DKK
Average target price
2,464
DKK
Spread / Average Target
+37.58%
- Stock Market
- Certificates
- Certificat
